TipRanks
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
US Market
IONS
Ionis Pharmaceuticals
RESEARCH TOOLSreports
Want to see IONS full AI Analyst Report?

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1,654 Followers
See the Price Targets and Ratings of:

IONS Analyst Ratings

Strong Buy
20Ratings
Strong Buy
17 Buy
3 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Ionis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$83.63
▲(31.56% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $83.63 with a high forecast of $104.00 and a low forecast of $54.00. The average price target represents a 31.56% change from the last price of $63.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","74":"$74","105":"$105","58.5":"$58.5","89.5":"$89.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.63157894736842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,58.5,74,89.5,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44,48.61538461538461,53.230769230769226,57.84615384615385,62.46153846153846,67.07692307692307,71.6923076923077,76.3076923076923,80.92307692307692,85.53846153846153,90.15384615384615,94.76923076923077,99.38461538461539,{"y":104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44,47.04858299595142,50.097165991902834,53.145748987854255,56.19433198380567,59.24291497975709,62.29149797570851,65.34008097165992,68.38866396761134,71.43724696356276,74.48582995951418,77.5344129554656,80.58299595141702,{"y":83.63157894736842,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44,44.76923076923077,45.53846153846154,46.30769230769231,47.07692307692308,47.84615384615385,48.61538461538461,49.38461538461539,50.15384615384615,50.92307692307692,51.69230769230769,52.46153846153846,53.23076923076923,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.19,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.77,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.88,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$104.00Average Price Target$83.63Lowest Price Target$54.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on IONS
Tiago Fauth
Raymond James
Raymond James
$84→$79
Buy
24.27%
Upside
Reiterated
10/20/26
Ionis Pharmaceuticals price target lowered to $79 from $84 at Raymond JamesIonis Pharmaceuticals price target lowered to $79 from $84 at Raymond James
UBS Analyst forecast on IONS
Joon Lee
UBS
UBS
$46→$88
Buy
38.43%
Upside
Upgraded
10/16/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Ionis Pharmaceuticals (NASDAQ: IONS)
Bank of America Securities Analyst forecast on IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$91
Buy
43.15%
Upside
Reiterated
10/09/26
Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities
H.C. Wainwright Analyst forecast on IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$100
Buy
57.31%
Upside
Reiterated
10/08/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)
RBC Capital Analyst forecast on IONS
Luca Issi
RBC Capital
RBC Capital
$85
Buy
33.71%
Upside
Reiterated
10/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on IONS
Justin Kim
Oppenheimer
Oppenheimer
$85
Buy
33.71%
Upside
Reiterated
09/24/26
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Canaccord Genuity Analyst forecast on IONS
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$85
Buy
33.71%
Upside
Reiterated
09/24/26
Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)
TD Cowen Analyst forecast on IONS
Yaron Werber
TD Cowen
TD Cowen
$84
Buy
32.14%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Ionis Pharmaceuticals (NASDAQ: IONS)
Needham Analyst forecast on IONS
Joseph Stringer
Needham
Needham
$86
Buy
35.28%
Upside
Reiterated
09/23/26
Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86
BMO Capital Analyst forecast on IONS
David Lebowitz
BMO Capital
BMO Capital
$54
Hold
-15.05%
Downside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: NanoViricides (NYSE MKT: NNVC) and Ionis Pharmaceuticals (NASDAQ: IONS)
William Blair Analyst forecast on IONS
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Ionis Pharmaceuticals (NASDAQ: IONS)
J.P. Morgan Analyst forecast on IONS
Jessica Fye
J.P. Morgan
J.P. Morgan
$70
Buy
10.11%
Upside
Assigned
09/22/26
Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorganIonis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan
Barclays Analyst forecast on IONS
Eliana Merle
Barclays
Barclays
$85
Buy
33.71%
Upside
Reiterated
09/18/26
Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Healthequity (HQY)
Guggenheim Analyst forecast on IONS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$89→$80
Buy
25.85%
Upside
Reiterated
09/14/26
Guggenheim Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
Goldman Sachs Analyst forecast on IONS
Salveen Richter
Goldman Sachs
Goldman Sachs
$69→$56
Hold
-11.91%
Downside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Axsome Therapeutics (NASDAQ: AXSM) and Ionis Pharmaceuticals (NASDAQ: IONS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on IONS
Tiago Fauth
Raymond James
Raymond James
$84→$79
Buy
24.27%
Upside
Reiterated
10/20/26
Ionis Pharmaceuticals price target lowered to $79 from $84 at Raymond JamesIonis Pharmaceuticals price target lowered to $79 from $84 at Raymond James
UBS Analyst forecast on IONS
Joon Lee
UBS
UBS
$46→$88
Buy
38.43%
Upside
Upgraded
10/16/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Ionis Pharmaceuticals (NASDAQ: IONS)
Bank of America Securities Analyst forecast on IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$91
Buy
43.15%
Upside
Reiterated
10/09/26
Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities
H.C. Wainwright Analyst forecast on IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$100
Buy
57.31%
Upside
Reiterated
10/08/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)
RBC Capital Analyst forecast on IONS
Luca Issi
RBC Capital
RBC Capital
$85
Buy
33.71%
Upside
Reiterated
10/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on IONS
Justin Kim
Oppenheimer
Oppenheimer
$85
Buy
33.71%
Upside
Reiterated
09/24/26
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Canaccord Genuity Analyst forecast on IONS
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$85
Buy
33.71%
Upside
Reiterated
09/24/26
Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)
TD Cowen Analyst forecast on IONS
Yaron Werber
TD Cowen
TD Cowen
$84
Buy
32.14%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Ionis Pharmaceuticals (NASDAQ: IONS)
Needham Analyst forecast on IONS
Joseph Stringer
Needham
Needham
$86
Buy
35.28%
Upside
Reiterated
09/23/26
Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86
BMO Capital Analyst forecast on IONS
David Lebowitz
BMO Capital
BMO Capital
$54
Hold
-15.05%
Downside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: NanoViricides (NYSE MKT: NNVC) and Ionis Pharmaceuticals (NASDAQ: IONS)
William Blair Analyst forecast on IONS
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Ionis Pharmaceuticals (NASDAQ: IONS)
J.P. Morgan Analyst forecast on IONS
Jessica Fye
J.P. Morgan
J.P. Morgan
$70
Buy
10.11%
Upside
Assigned
09/22/26
Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorganIonis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan
Barclays Analyst forecast on IONS
Eliana Merle
Barclays
Barclays
$85
Buy
33.71%
Upside
Reiterated
09/18/26
Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Healthequity (HQY)
Guggenheim Analyst forecast on IONS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$89→$80
Buy
25.85%
Upside
Reiterated
09/14/26
Guggenheim Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
Goldman Sachs Analyst forecast on IONS
Salveen Richter
Goldman Sachs
Goldman Sachs
$69→$56
Hold
-11.91%
Downside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Axsome Therapeutics (NASDAQ: AXSM) and Ionis Pharmaceuticals (NASDAQ: IONS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
OVIDOvid Therapeutics
OMCLOmnicell
IMUXImmunic
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months
Mitchell KapoorH.C. Wainwright
Success Rate
10/18 ratings generated profit
56%
Average Return
+16.52%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +16.52% per trade.
1 Year
Gary NachmanCanaccord Genuity
Success Rate
16/27 ratings generated profit
59%
Average Return
+17.65%
Copying Gary Nachman's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +17.65% per trade.
2 Years
Yanan ZhuWells Fargo
Success Rate
22/29 ratings generated profit
76%
Average Return
+22.67%
Copying Yanan Zhu's trades and holding each position for 2 Years would result in 75.86% of your transactions generating a profit, with an average return of +22.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
15
35
39
50
30
Buy
35
27
24
20
11
Hold
2
5
9
13
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
52
67
72
83
50
In the current month, IONS has received 41 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 83.63.
Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.21 with a range of -$1.42 to -$0.96. The previous quarter’s EPS was -$0.69. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s earnings estimate for IONS is -$1.21 with a range of -$1.42 to -$0.96. The previous quarter’s EPS was -$0.69. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $183.30M with a range of $160.00M to $225.00M. The previous quarter’s sales results were $267.95M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s sales forecast for IONS is $183.30M with a range of $160.00M to $225.00M. The previous quarter’s sales results were $267.95M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 83.63.
    What is IONS’s upside potential, based on the analysts’ average price target?
    Ionis Pharmaceuticals has 31.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IONS a Buy, Sell or Hold?
          Ionis Pharmaceuticals has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Ionis Pharmaceuticals’s price target?
            The average price target for Ionis Pharmaceuticals is 83.63. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $104.00 ,the lowest forecast is $54.00. The average price target represents 31.56% Increase from the current price of $63.57.
              What do analysts say about Ionis Pharmaceuticals?
              Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of IONS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.